@2024 - All Right Reserved.

The FDA has given tentative approval to the abbreviated new drug application (ANDA) for PNT2003, a radioequivalent version of lutetium Lu 177 dotatate (Lutathera) indicated for treatment of ...

St Bartholomew's Hospital and The James Cook University Hospital mark key UK expansion of the company's Phase 2 mCRPC programme The patients received Lutetium (177 Lu) rhPSMA-10.1 Injections at both ...

or on the link below. ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid ...

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with radioligand intensification despite early on-treatment score fluctuations. FACT-P ...

Please provide your email address to receive an email when new articles are posted on . Zibelman discusses studies on PSMA-targeted therapies, along with updates from the TheraP trial and VISION ...

Lu-177 dotatate is a molecular therapy. It is a type of peptide receptor radionuclide therapy (PRRT) used mainly for neuroendocrine tumors (NETs). PRRT combines a compound called a peptide with a ...

Prostate-specific membrane antigen (PSMA) is a protein found in small amounts in your prostate gland. When you have prostate cancer, you have many times more PSMA than normal. This makes PSMA a good ...

For patients with metastatic prostate cancer who have exhausted initial or first-line treatments like hormone therapy (also called androgen deprivation therapy or ADT) and chemotherapy, a promising ...